In this video, James E. Galvin, MD, MPH, professor of neurology and psychiatry and behavioral sciences at the University of Miami Miller School of Medicine, discusses how the treatment landscape for ...

Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago. The drugmaker also said Wednesday that it will ...

The U.S. Food and Drug Administration's approval of Biogen's Alzheimer's drug Aduhelm in June was heralded as a historic triumph in the fight against a disease that kills thousands of Americans every ...

Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing, ...

A handful of Blue Cross and Blue Shield affiliates announced Aduhelm, Biogen’s controversial Alzehimer’s drug, would not be covered after being deemed experimental and investigational. “We have ...

CMS intends for Medicare to cover Aduhelm, Biogen’s Alzheimer’s disease treatment, for patients taking part in clinical trials, the agency announced Jan. 11. The national coverage determination ...

Department of Health and Human Services Secretary Xavier Becerra announced Monday that he has ordered Medicare to "reassess" the agency's 2022 premium rate hike for Medicare Part B, citing Biogen's ...

News moves fast, and there's not always time to untangle the complex forces driving the day's biggest stories. WSJ Explains breaks down big market moves, business and economic trends, and scientific ...

A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's accelerated approval process, and is using treatments from Sarepta Therapeutics ...

With a market cap of $17.4 billion, Biogen Inc. (BIIB) is a global biotechnology leader focused on discovering, developing, and delivering innovative therapies for serious neurological and ...

The release by the U.S. CMS of the final national coverage determination (NCD) for Biogen Inc.’s Alzheimer disease (AD) drug, Aduhelm (aducanumab), lit speculation on the meaning for others in the ...